Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degenera… Read more
Regeneron Pharmaceuticals Inc (REGN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.037x
Based on the latest financial reports, Regeneron Pharmaceuticals Inc (REGN) has a cash flow conversion efficiency ratio of 0.037x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.17 Billion) by net assets ($31.26 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Regeneron Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1991–2025)
This chart illustrates how Regeneron Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Regeneron Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Regeneron Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Johnson Controls International PLC
NYSE:JCI
|
-0.034x |
|
Safran SA
PINK:SAFRF
|
0.200x |
|
Marriott International Inc
NASDAQ:MAR
|
-0.220x |
|
AIA Group Ltd
PINK:AAIGF
|
0.123x |
|
O’Reilly Automotive Inc
NASDAQ:ORLY
|
-0.830x |
|
Cummins Inc
NYSE:CMI
|
0.114x |
|
Triumph Financial Inc
NASDAQ:TFINP
|
-0.033x |
|
Emerson Electric Company
NYSE:EMR
|
0.034x |
Annual Cash Flow Conversion Efficiency for Regeneron Pharmaceuticals Inc (1991–2025)
The table below shows the annual cash flow conversion efficiency of Regeneron Pharmaceuticals Inc from 1991 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $31.26 Billion | $4.98 Billion | 0.159x | +5.77% |
| 2024-12-31 | $29.35 Billion | $4.42 Billion | 0.151x | -14.86% |
| 2023-12-31 | $25.97 Billion | $4.59 Billion | 0.177x | -20.06% |
| 2022-12-31 | $22.66 Billion | $5.01 Billion | 0.221x | -41.35% |
| 2021-12-31 | $18.77 Billion | $7.08 Billion | 0.377x | +58.88% |
| 2020-12-31 | $11.03 Billion | $2.62 Billion | 0.237x | +8.37% |
| 2019-12-31 | $11.09 Billion | $2.43 Billion | 0.219x | -12.58% |
| 2018-12-31 | $8.76 Billion | $2.20 Billion | 0.251x | +17.82% |
| 2017-12-31 | $6.14 Billion | $1.31 Billion | 0.213x | -36.30% |
| 2016-12-31 | $4.45 Billion | $1.49 Billion | 0.334x | -8.28% |
| 2015-12-31 | $3.65 Billion | $1.33 Billion | 0.364x | +23.03% |
| 2014-12-31 | $2.54 Billion | $752.43 Million | 0.296x | -1.84% |
| 2013-12-31 | $1.95 Billion | $588.60 Million | 0.302x | +603.27% |
| 2012-12-31 | $1.25 Billion | $-74.61 Million | -0.060x | +79.46% |
| 2011-12-31 | $485.73 Million | $-141.68 Million | -0.292x | -259.80% |
| 2010-12-31 | $527.82 Million | $96.34 Million | 0.183x | +200.27% |
| 2009-12-31 | $396.76 Million | $-72.23 Million | -0.182x | +14.41% |
| 2008-12-31 | $418.85 Million | $-89.09 Million | -0.213x | -457.65% |
| 2007-12-31 | $460.27 Million | $27.37 Million | 0.059x | -44.17% |
| 2006-12-31 | $216.62 Million | $23.07 Million | 0.107x | +140.08% |
| 2005-12-31 | $114.00 Million | $-30.30 Million | -0.266x | -186.89% |
| 2004-12-31 | $182.54 Million | $-16.91 Million | -0.093x | -107.89% |
| 2003-12-31 | $137.64 Million | $-6.13 Million | -0.045x | +94.11% |
| 2002-12-31 | $145.98 Million | $-110.52 Million | -0.757x | -251.81% |
| 2001-12-31 | $266.36 Million | $-57.32 Million | -0.215x | -40.43% |
| 2000-12-31 | $182.13 Million | $-27.91 Million | -0.153x | -21.59% |
| 1999-12-31 | $109.50 Million | $-13.80 Million | -0.126x | -62.11% |
| 1998-12-31 | $131.20 Million | $-10.20 Million | -0.078x | -77.03% |
| 1997-12-31 | $138.90 Million | $-6.10 Million | -0.044x | +76.87% |
| 1996-12-31 | $106.90 Million | $-20.30 Million | -0.190x | +29.15% |
| 1995-12-31 | $67.90 Million | $-18.20 Million | -0.268x | +12.27% |
| 1994-12-31 | $67.10 Million | $-20.50 Million | -0.306x | +0.12% |
| 1993-12-31 | $98.40 Million | $-30.10 Million | -0.306x | -55.08% |
| 1992-12-31 | $87.20 Million | $-17.20 Million | -0.197x | -208.05% |
| 1991-12-31 | $106.20 Million | $-6.80 Million | -0.064x | -- |